Charles Schwab’s Kymera Therapeutics KYMR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $18.7M | Buy |
429,304
+47,596
| +12% | +$2.08M | ﹤0.01% | 1711 |
|
|
2025
Q1 | $10.4M | Sell |
381,708
-5,479
| -1% | -$150K | ﹤0.01% | 1932 |
|
|
2024
Q4 | $15.6M | Buy |
387,187
+20,346
| +6% | +$819K | ﹤0.01% | 1822 |
|
|
2024
Q3 | $17.4M | Sell |
366,841
-8,260
| -2% | -$391K | ﹤0.01% | 1773 |
|
|
2024
Q2 | $11.2M | Buy |
375,101
+20,995
| +6% | +$627K | ﹤0.01% | 1992 |
|
|
2024
Q1 | $14.2M | Buy |
354,106
+47,414
| +15% | +$1.91M | ﹤0.01% | 1809 |
|
|
2023
Q4 | $7.81M | Buy |
306,692
+4,951
| +2% | +$126K | ﹤0.01% | 2120 |
|
|
2023
Q3 | $4.19M | Buy |
301,741
+639
| +0.2% | +$8.88K | ﹤0.01% | 2333 |
|
|
2023
Q2 | $6.92M | Buy |
301,102
+2,605
| +0.9% | +$59.9K | ﹤0.01% | 2081 |
|
|
2023
Q1 | $8.84M | Buy |
298,497
+589
| +0.2% | +$17.5K | ﹤0.01% | 1929 |
|
|
2022
Q4 | $7.44M | Buy |
297,908
+19,348
| +7% | +$483K | ﹤0.01% | 2008 |
|
|
2022
Q3 | $6.07M | Buy |
278,560
+22,018
| +9% | +$479K | ﹤0.01% | 2116 |
|
|
2022
Q2 | $5.05M | Buy |
256,542
+1,265
| +0.5% | +$24.9K | ﹤0.01% | 2181 |
|
|
2022
Q1 | $10.8M | Buy |
255,277
+6,743
| +3% | +$285K | ﹤0.01% | 1914 |
|
|
2021
Q4 | $15.8M | Buy |
248,534
+5,309
| +2% | +$337K | ﹤0.01% | 1751 |
|
|
2021
Q3 | $14.3M | Buy |
243,225
+139,149
| +134% | +$8.17M | ﹤0.01% | 1810 |
|
|
2021
Q2 | $5.05M | Buy |
104,076
+41,628
| +67% | +$2.02M | ﹤0.01% | 2352 |
|
|
2021
Q1 | $2.43M | Buy |
62,448
+1,114
| +2% | +$43.3K | ﹤0.01% | 2607 |
|
|
2020
Q4 | $3.8M | Buy |
+61,334
| New | +$3.8M | ﹤0.01% | 2349 |
|